The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab

References

• Bellmunt J, Wit RD, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa161368328212060
   PubMed Web of Science ®Google Scholar
• Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–1230. doi:10.1056/NEJMoa200278832945632
   PubMed Web of Science ®Google Scholar
• Grisay G, Pierrard J, Confente C, et al. Future strategies involving immune checkpoint inhibitors in advanced urothelial carcinoma. Curr Treat Options Oncol. 2020;22(1):7. doi:10.1007/s11864-020-00799-933269438
   PubMed Web of Science ®Google Scholar
• Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther. 2018;11:955–965. doi:10.2147/OTT.S15329029503570
   PubMed Web of Science ®Google Scholar
• Kawai T, Sato Y, Makino K, et al. Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients. Eur J Cancer. 2019;116:114–115. doi:10.1016/j.ejca.2019.05.01731195355
   PubMed Web of Science ®Google Scholar
• Yasuoka S, Yuasa T, Nishimura N, et al. Initial experience of pembrolizumab therapy in Japanese patients with metastatic urothelial cancer. Anticancer Res. 2019;39(7):3887–3892. doi:10.21873/anticanres.1353931262917
   PubMed Web of Science ®Google Scholar
• Ogihara K, Kikuchi E, Shigeta K, et al. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients. Urol Oncol. 2020;38(6):602.e1–602.e10. doi:10.1016/j.urolonc.2020.02.005
   PubMed Web of Science ®Google Scholar
• Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016;22(22):5487–5496. doi:10.1158/1078-0432.CCR-16-012727185375
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Haratani K, Hayashi H, et al. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol. 2018;13(1):97–105. doi:10.1016/j.jtho.2017.10.03029170120
   PubMed Web of Science ®Google Scholar
• Zahoor H, Barata PC, Jia X, et al. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. J Immunother Cancer. 2018;6(1):107. doi:10.1186/s40425-018-0425-830333065
   PubMed Web of Science ®Google Scholar
• Gebhardt C, Sevko A, Jiang H, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res. 2015;21(24):5453–5459. doi:10.1158/1078-0432.CCR-15-067626289067
   PubMed Web of Science ®Google Scholar
• Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013;24(6):1697–1703. doi:10.1093/annonc/mdt02723439861
   PubMed Web of Science ®Google Scholar
• Ohashi H, Takeuchi S, Miyagaki T, et al. Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma. Drug Discov Ther. 2020;14(3):117–121. doi:10.5582/ddt.2020.0304332595179
   PubMed Web of Science ®Google Scholar
• Okauchi S, Shiozawa T, Miyazaki K, et al. Association between peripheral eosinophils and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Pol Arch Intern Med. 2021;131(2):152–160. doi:10.20452/pamw.1577633491942
   PubMedGoogle Scholar
• Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. doi:10.1016/j.eururo.2016.02.02926935559
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Yatsuda J, Shimokawa M, et al. Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma. Int J Clin Oncol. 2021;26(1):169–177. doi:10.1007/s10147-020-01784-w32948925
   PubMed Web of Science ®Google Scholar
• Klion AD, Ackerman SJ, Bochner BS. Contributions of eosinophils to human health and disease. Annu Rev Pathol. 2020;15(1):179–209. doi:10.1146/annurev-pathmechdis-012419-03275631977298
   PubMed Web of Science ®Google Scholar
• Krishnan T, Tomita Y, Roberts-Thomson R. A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy. Future Sci OA. 2020;6(10):FSO608. doi:10.2144/fsoa-2020-007033312694
   PubMed Web of Science ®Google Scholar
• Davis BP, Rothenberg ME. Eosinophils and cancer. Cancer Immunol Res. 2014;2(1):1–8. doi:10.1158/2326-6066.CIR-13-019624778159
   PubMed Web of Science ®Google Scholar
• Simon SCS, Utikal J, Umansky V. Opposing roles of eosinophils in cancer. Cancer Immunol Immunother. 2019;68(5):823–833. doi:10.1007/s00262-018-2255-430302498
   PubMed Web of Science ®Google Scholar
• Mota JM, Teo MY, Whiting K, et al. Pretreatment eosinophil counts in patients with advanced or metastatic urothelial carcinoma treated with anti-PD-1/PD-L1 checkpoint inhibitors. J Immunother. 2021;44(7):248–253. doi:10.1097/CJI.000000000000037234081050
   PubMed Web of Science ®Google Scholar
• Matthew D, Tucker MD. Association between Neutrophil-to-Eosinophil Ratio (NER) and efficacy outcomes in the JAVELIN renal 101 study. ASCO 2021. Available from: https://www.urotoday.com/conference-highlights/asco-2021/asco-2021-kidney-cancer/130142-asco-2021-association-between-neutrophil-to-eosinophil-ratio-ner-and-efficacy-outcomes-in-the-javelin-renal-101-study.html. Accessed September 19, 2021.
   Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115. doi:10.1056/NEJMoa181604730779531
   PubMed Web of Science ®Google Scholar